Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer: A Multicenter, Prospective, Randomized Controlled Cohort Study (FINE Trial)

NCT05954078 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05954078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05954078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer: A Multicenter, Prospective, Randomized Controlled Cohort Study (FINE Trial)
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Recruiting
Start date
August 1, 2023
Completion date
June 30, 2028
Enrollment
340 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

circulating tumor dna methylation, high-risk stage ii colorectal cancer, stage iii colorectal cancer